Related Experiment Video
Updated: Aug 24, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
[Chronic hepatitis C--therapeutic modalities for interferon failure]
1Abteilung für Gastroenterologie, Medizinische Klinik C, Kantonsspital St. Gallen.
Abstract:
Treatment with alpha-interferon-monotherapy for chronic hepatitis C is rather unsatisfactory. After a 6-12-months course of interferon three times 3 MU weekly, only a minority of 10-25% of interferon-naive patients have a sustained response with normalisation of ALT and elimination of viremia. The majority of patients does not respond or relapses shortly after treatment. In these patients an individual risk factor profile should be worked out based on evaluation of known factors predictive for response which may aid in the therapeutic decision concerning indication and type of a second line treatment. This review on current therapeutic options for second line treatment focuses on interferon-retreatment and combination therapy with ribavirin and amantadine.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Cirrhosis II: Pathophysiology

